GeneFerm Biotechnology , Ltd. Receivables

The latest receivables for 1796.TWO is $78M as of June 2026. That compares with $100M in the prior-year period — down 24.8% year over year. Investors often review this figure alongside GeneFerm Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 1796.TWO's receivables moved from $100M to $78M — a 24.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneFerm Biotechnology , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $78M for 1796.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 1796.TWO's receivables ($78M), review year-over-year change from $100M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.